Regeneron Pharmaceuticals, Inc. (REGN) RBC Capital Markets Global Healthcare Conference (Transcript)

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) RBC Capital Markets Global Healthcare Conference May 20, 2025 11:00 AM ET

Company Participants

Mark Hudson – Senior Director of Investor Relations
George D. Yancopoulos – Board Co-Chair, President and Chief Scientific Officer

Conference Call Participants

Brian Abrahams – RBC Capital Markets

Brian Abrahams

Our next featured company, Regeneron, has always been known for its R&D engine. And, there’s a lot more coming from their pipeline, really over the next 6 months to 12 months and beyond. And, the architect of that has been their Board Co-Chair, President, and CSO, George Yancopoulos. So, we’re really pleased to have George with us today, and alongside him on the stage, Mark Hudson, Senior Director of IR for Regeneron. So, thanks again for joining us and looking forward to the discussion.

George D. Yancopoulos

Appreciate you’re having us. Go ahead, Mark.

Mark Hudson

Yes. And, before we get started, obviously, I have to read a forward-looking statement. Otherwise, my, legal folks will get mad at me. So, I’d like to remind you that, remarks made today may include forward-looking statements about Regeneron, and each forward-looking statement is subject to risk and uncertainties that could cause actual results and events to differ materially from those projected such statement. Description of material risks and uncertainties can be found in Regeneron’s SEC filings.

Regeneron does not undertake any obligation to update any forward-looking statement whether as a result of new information, future events or otherwise.

And, it’s a pleasure to be here, Brian, and we’re glad, we have George with us. So, we’ll get right into Q&A.

Question-And-Answer Session

Q – Brian Abrahams

Thanks. So, why don’t we start with the next upcoming catalyst, Phase 3 data for Itepekimab and COPD? Can you tell us what you’ve learned from the prior data in asthma and COPD